Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
about
Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic DiseasesRomidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataStudies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathwayCancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, VorinostatRomidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction networkVorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.Histone deacetylase inhibitors: emerging mechanisms of resistance.The use of molecular profiling for diagnosis and research in non-Hodgkin's lymphomaTargeting Histone Deacetylases in Diseases: Where Are We?HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.Cutaneous T-cell lymphomas: a review of new discoveries and treatments.HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.The PIM family of serine/threonine kinases in cancer.From empiric to mechanism-based therapy for peripheral T cell lymphoma.PIM kinases: an overview in tumors and recent advances in pancreatic cancer.Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach.Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonBlockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis.Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.
P2860
Q28079715-0B5F271E-192D-4412-80CC-1C5A525926E3Q30936712-D65096B5-2B00-43AF-861A-61A99AF3E60AQ33570972-D278714B-2439-4142-BF7A-BB3E12AA0F5AQ34023553-6E6F0311-6EC4-4CBB-97AB-1D279B506817Q34213967-64F5F04F-EED7-47F4-94AB-8CBA68A9C328Q34394171-3962B455-1477-48F7-92AA-AC57DF16FF05Q34414452-7E166261-9081-4591-BD44-3DFF948F34B9Q34468386-BEAF0C19-7977-43D7-A0C0-266EE35D15D5Q34587139-F635A99A-DAA5-4FDF-8B98-C1515CF78E7AQ34672100-9AE798F2-A7A6-4C38-BF58-DE141D6D0320Q35026864-D04237E9-0AAF-434B-A831-71672FA97F17Q35592607-A2907BBA-12FD-45D3-9039-AA42E45A0E49Q35716007-5BE74761-1261-4420-8289-F43CE27D52BCQ35821728-684B9A3E-AE94-4CCC-ADE3-31688EC7223DQ37002069-B08E4960-FC2A-4A79-9651-B6E0C0C9111CQ37119662-877E1BEE-7F3A-488B-A3D4-1D79F5F2C39EQ37821337-0DA9FF6B-96E5-4CC2-9889-50B02D1EEE01Q37981969-195E8ED4-CBB9-40C4-8A4F-ACBDFD612B27Q37993586-CACBB23C-E735-4936-8B1C-42A7131F6808Q37998019-E106D90D-C90E-4A79-BC43-824A16028239Q38098139-517D4644-A010-406C-AC9A-C994A91ED7F1Q38186617-1BD8064B-33F0-45A0-BA1D-EC6A3DC6870EQ38209606-E1EA4744-CB12-4BDE-A92D-50985B104E27Q38431434-FFD1583F-AFA3-4F85-B256-B0643A144802Q38458190-BDDBD355-EC34-4805-A9F4-0A00CBE6E253Q38478630-3575A495-8CA6-4404-960A-9B9047D4E31BQ39310876-9A9C7C9E-E1EB-465B-880A-A931CA8828E5Q39608513-BF878CFB-6E7C-41AE-BB9F-FFD060DCE1C2Q39620587-45D877B9-9B0C-4C0E-8143-ED7562D9135EQ47140442-9260DD6E-DDAC-4F25-9026-86A5009B7DEDQ49359645-ABE91A9B-7AAE-4B26-8CE6-ECAAEBDF53E9Q50117976-DCA36DE3-A656-4E77-AE2D-7ABD439776DDQ51584555-67D03D0B-D1CE-4FA9-A322-1CC124E2B664Q52581847-C02C27EA-5B20-43B5-AE1F-8E02DB3B3322
P2860
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Vorinostat interferes with the ...... in cutaneous T-cell lymphoma.
@ast
Vorinostat interferes with the ...... in cutaneous T-cell lymphoma.
@en
type
label
Vorinostat interferes with the ...... in cutaneous T-cell lymphoma.
@ast
Vorinostat interferes with the ...... in cutaneous T-cell lymphoma.
@en
prefLabel
Vorinostat interferes with the ...... in cutaneous T-cell lymphoma.
@ast
Vorinostat interferes with the ...... in cutaneous T-cell lymphoma.
@en
P2093
P2860
P50
P1433
P1476
Vorinostat interferes with the ...... s in cutaneous T-cell lymphoma
@en
P2093
Beatriz Herreros
Carmen Blanco Aparicio
James R Bischoff
Ma Elena Rodriguez
Magdalena B Wozniak
Maria I Longo
Marta Herrera
Pablo L Ortiz-Romero
Paloma de La Cueva
Raquel Villuendas
P2860
P304
P356
10.3324/HAEMATOL.2009.013870
P577
2010-02-04T00:00:00Z